59257-86-2

Basic information

• Product Name: 7-(benzyloxy)-2,2-dimethylchroman-4-one
• Synonyms: 7-(benzyloxy)-2,2-dimethylchroman-4-one
• CAS NO: 59257-86-2
• Molecular Weight: 0
• Mol File: 59257-86-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 7-(benzyloxy)-2,2-dimethylchroman-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(benzyloxy)-2,2-dimethylchroman-4-one(59257-86-2)
• EPA Substance Registry System: 7-(benzyloxy)-2,2-dimethylchroman-4-one(59257-86-2)

Safety Data

• Hazardous Substances Data: 59257-86-2(Hazardous Substances Data)

Upstream product

• 67716-21-6 3-bromo-3-methyl-butyryl chloride 
• 3350-78-5 3,3-Dimethylacryloyl chloride 
• 108-46-3 recorcinol 
• 99323-00-9 1-(2',4'-dihydroxyphenyl)-3-methyl-but-2-en-1-one 
• 541-47-9 3-Methylbutenoic acid 
• 17771-33-4 7-hydroxy-2,2-dimethyl-chroman-4-one 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 

Downstream Products

• 1242939-78-1 7-benzyloxy-6-iodo-2,2-dimethyl-4-chromanone 
• 1242939-75-8 7-benzyloxy-3-iodo-2,2-dimethyl-4-chromanone 
• 94243-90-0 7-(benzyloxy)-2,2-dimethyl-2H-1-benzopyran 
• 144537-25-7 8-Benzyloxy-2,2-dimethyl-3,4-dihydro-2H-benzo[f][1,4]oxazepin-5-one 
• 120046-38-0 7-Benzyloxy-2,2-dimethyl-chroman-4-ol 

Relevant articles and documents

Chromanones: selective and reversible monoamine oxidase B inhibitors with nanomolar potency

A new series of C7-substituted chromanones has been designed, synthesized and evaluated for hMAO-B inhibitory activity in vitro. Most of the studied compounds were remarkably potent and selective MAO-B inhibitors and showed weak or no inhibition of MAO-A. Especially, compound 4f (IC50 = 8.62 nM) was the best MAO-B inhibitor and exhibited the highest selectivity for MAO-B (SI > 11 627.9-fold). In addition, the structure-activity relationships for MAO-B inhibition indicated that substitutions at the C7 of the chromanone moiety, particularly with the halogen substituted benzyloxy, were more favorable for MAO-B inhibition. Molecular docking studies have been performed to explore the interaction modes of C7-substituted chromanones with MAO-B. Furthermore, the representative compounds 4f and 5d showed low neurotoxicity in SH-SY5Y cells in vitro. So the C7-substituted chromanones could be used to develop promising drug candidates for the therapy of neurodegenerative diseases.

Compounds and methods

This invention relates to substituted benzo[1,2-b:5,4-b′]dipyran-4-amines which are modulators, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and a topic disorders (for example, a topic dermatitis and allergies), rheumatoid arthritis, sarcoidosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease, all in mammals, by the use of substituted benzo[1,2-b:5,4-b′]dipyran-4-amines which are CCR5 receptor antagonists. Furthermore, since CD8+T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therpeutic in the treatment of COPD. Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.